Also known as AZD 9291, AZD-9291, AZD9291, mereletinib (obsolete INN), Tagrisso®, Mereletinib, N-(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide
~7 min read
{{Infobox drug | verifiedrevid = | image = Osimertinib.svg | image_class = skin-invert-image | width = 250 | alt = | USAN = osimertinib mesylate | JAN = osimertinib mesilate
| tradename = Tagrisso, others | Drugs.com = | MedlinePlus = a616005 | DailyMedID = Osimertinib | pregnancy_AU = D | routes_of_administration = By mouth | ATC_prefix = L01 | ATC_suffix = EB04
Osimertinib, sold under the brand name Tagrisso, is a medication used to treat non-small-cell lung carcinomas with specific mutations. It is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor.
via Wikipedia infobox
via PubMed
via Wikidata sitelinks · CC0
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).